Advanced searches left 3/3

Diabetic Macular Edema - Crossref

Summarized by Plex Scholar
Last Updated: 02 August 2022

* If you want to update the article please login/register

Anatomical and Functional Effects of Oral Administration of Curcuma Longa and Boswellia Serrata Combination in Patients with Treatment-Naïve Diabetic Macular Edema

Endothelial cell growth factor, which now provides the treatment for diabetic macular edema. This paper was designed to investigate the effects of oral administration of Curcuma longa and Boswellia serrata in patients with non-proliferative diabetic retinopathy and treatment-nau00efve DME 400 mm during the COVID-19 pandemic. According to Retimixu00ae's consumption, a mixed-design ANOVA was calculated to see if the change in CMT and BCVA over time would change over time. The relationship between time and care was significant, with F = 14. 416; u03b72 = 0. 127; p 0. 001, indicating that the change in CMT and BCVA among groups over time was significantly different. In keeping baseline CMT and BCVA values over time, our results show the efficacy of Curcuma longa and Boswellia serrata in patients with non-proliferative DR and treatment-nau00efve DME.

Source link: https://doi.org/10.3390/jcm11154451


The Narrative Medicine Approach in the Treatment of Diabetic Macular Edema: An Italian Experience

The study explores the clinical path of patients affected by diabetic macular edema through the direct voice of patients and caregivers by using a u201cpatient journey u201d and narrative method approach. A multidisciplinary board of health professionals supervised the patient's journey, and four Italian retina centers were involved in the mapping of the patient's journey. According to the narrative medicine perspective, DME patients on intravitreal injection therapy and caregivers were interviewed. The research involved four research centers in Italy and collected a total of 106 narratives, 82 from DME patients and 24 from caregivers. DME reduces the quality of life of patients affected by the disease. The narrative medicine approach provides qualitative and emotional patient-guided details. The patient journey gives all of those involved in the care of DME with flowcharts to refer to, identifying the key points in the healthcare journey of DME patients to ensure the disease's management.

Source link: https://doi.org/10.3390/ijerph19159367


Foveal eversion patterns in diabetic macular edema

Abstract The aim of the current study was to describe foveal eversion patterns in diabetic macular edema and to determine their relationship with the disease's course and results. Patients were divided into two groups, one group being treated by recombinant anti-VEGF injections and dexamethasone implants, and the other being treated by fluocinolone acetonide implant with additional anti-VEGF retreatments if required. One hundred and forty-six eyes affected by already treated DME, with 84 eyes treated with anti-VEGF/DEX medications and 62 treated with FAc implant. 84 eyes were treated with anti-VEGF injections before being accepted into the study, while 64 eyes underwent a combination of anti-VEGF and corticosteroids implants. In 83 eyes, aversion pattern was observed; Pattern 1a; Pattern 1b; and Pattern 2; Pattern 1b and Pattern 2; and Pattern 2; a tiger eversion was discovered in 83 eyes. The increased incidence of persistent DME remained in Pattern 1b and Pattern 2 for a long time.

Source link: https://doi.org/10.1038/s41598-022-17555-8


Analysis of Cytokines in the Aqueous Humor During Intravitreal Treatment With Ranibizumab in Diabetic Macular Edema

Patients with EMD with peripheral ischemia are excluded from Group 1 of Patients with EMD without peripheral ischemia, according to Group 1. Patients with EMD with peripheral ischemia, patients with peripheral ischemia in Group 2, patients with Group 2, patients with EMD with peripheral ischemia, are the victims. Patients with systemic and/or eye diseases are among the control group for Group 3, a control group that was established by patients without systemic and/or eye disease. Patients in groups 1 and 2 were treated with three intravitreal injections of 2 mg/0. 05 ml of ranibizumab, with intervals of approximately 30 days. Results: : The medians of IL-6 concentrations in group 1 and group 2 showed a statistically significant rise, but not significantly different, during therapy. In the group without ischemia or a decrease in VEGF in both groups, there were statistically significant differences in the rise of their median levels in interleukin 6 in both groups.

Source link: https://doi.org/10.21203/rs.3.rs-803720/v1


Short-term Outcomes of Refractory Diabetic Macular Edema Switch from Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience.

Abstract Background: In a refractory diabetic macular edema treated by intravitreal ranibizumab, we need to determine the safety and quality of intravitreal dexamethasone implants. We retrospectively reviewed DME patients who received DEX implant therapy after being unresponsive to at least three monthly intravitreal ranibizumab injections. Twenty-nine eyes of 26 patients who had previously received an average of 8. 1 b1 4. 4 ranibizumab injections were included in this study. CRT and worse BCVA were both correlated with improved therapeutic outcomes in the geriatric setting. In real life, converting to DEX Implant is fast and safe for treating DME non-responders to intravitreal ranibizumab.

Source link: https://doi.org/10.21203/rs.3.rs-104770/v1


Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes

For nau00efve and PT DME eyes over 24 months, a number of IDI injections, percentage of eyes with 1, 2, 3 and u00b3 4 injections, time to reinjections, visual acuity, intraocular pressure, and central retinal thickness were analyzed. In nau00eff vs. PT DME eyes, the percentage of eyes receiving 1 injection was significantly higher. nau00efve versus PT DME eyes was significantly higher. At all reported timepoints, VA scores were consistently higher in nau00efve vs. PT DME eyes, with no significant differences in CRT reduction or adverse effect rates. Conclusion: In a real-world setting, Nau00efve DME eyes received fewer IDI injections and showed higher VA levels than PT DME eyes for 24 months. This information supports IDI use in early DME stages and provides further evidence of improved IDI response when used as first-line therapy.

Source link: https://doi.org/10.21203/rs.3.rs-68436/v2


Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes

In a real-life situation, the goal was to identify several response patterns to intravitreal dexamethasone implants in naefve and previously treated diabetic macular edema eyes. For nau00efve and previously treated DME eyes over 24 months, the number of IDI injections, percentage of eyes with 1, 2,3 and u22654 injections, time to reinjections, visual acuity, intraocular pressure, and central retinal thickness were investigated. In nau00efve vs. PT DME eyes, the percentage of eyes receiving 1, 2, or 3 injections was much lower, but no changes were found in eyes receiving u22654 injections. At all measured timepoints, VA scores were consistently higher in naefve vs. PT DME eyes, with no significant differences in CRT reduction or adverse effect rates. In a real-world setting, Na00efve DME eyes required fewer IDI injections and maintained higher VA levels than PT DME eyes for 24 months.

Source link: https://doi.org/10.21203/rs.3.rs-68436/v1


Systemic and local diseases associated with the development of diabetic macular edema among Japanese patients with diabetes mellitus

The reason for the glaucoma loss of patients with diabetes mellitus is a diabetic macular edema. Methods An analysis of the Methods A total of 3. 11 million Japanese subjects who had registered in the Japan Medical Data Center's database from 2005 to 2014 was examined. Patients with DME were diagnosed one year before the manufacture of DME in patients with DME, and one year before the last visit to an ophthalmic clinic with patients without DME was found. Results (including 17,403 patients with DM who met the inclusion and exclusion criteria, and 420 patients developed DME.

Source link: https://doi.org/10.21203/rs.3.rs-22340/v1


Influence of Segmental Supply of Cilioretinal Artery on Morphology of Diabetic Macular Edema

Methods : A retrospective review Methods : Our aim is to determine the sourcing of CRA with non-involving and center-involving diabetic edema. Our goal is to determine the availability of CRA with segments of macular edema with segments of macular edema, which presence of CRA. Maximum retinal thickness was noted at the superior quadrant 293. 64 mm and had non-involving DME 194. 87. 76 mm and center-involving DME 194. 85. 06 mm, and when CRA supplied the lower area, maximum retinal thickness was noted at the nasal quadrant 293. 79 mm with center-involving DME 292. 00. 69mm and center-involving DME 194. 87. 79 mm.

Source link: https://doi.org/10.21203/rs.2.21876/v2


Influence of Segmental Supply of Cilioretinal Artery on Morphology of Diabetic Macular Edema

Methods and Materials A retrospective analysis in which forty-three patients with different stages of diabetic retinopathy were found in a multi-stage retinopathy with the presence of CRA. Our aim is to determine the exact location of CRA with non-involving and center-involving diabetic macular edema DME and center-involving diabetic macular edema with segments of macular edema design Methods and Materials Since the supply of CRA is segmental, The results of the evaluation in three subjects and bilateral CRA in three subjects showed unilateral CRA in 26 men and 17 women of various groups of diabetic retinopathy.

Source link: https://doi.org/10.21203/rs.2.21876/v1

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions